Marietta, Ga.-based MiMedx Group has announced Health Care Services Corporation will now reimburse for MiMedx's EpiFix allograft.
Approved reimbursement uses for the device include wound care, soft tissue replacement as in burn repair, cardiovascular applications, treatment and ocular surfaces and surgical barrier application in knee and spine surgeries, according to a news release.
At this time, 12 state Medicaid programs also reimburse for EpiFix, according to the release.